At the same time, our data show a clear trend toward progressively earlier use of cenobamate across successive cohorts, with patients initiating treatment after fewer prior lines of therapy.
← all excerpts
Characteristics, therapeutic pathway and the economic burden of patients with drug-resistant epilepsy: A real-world analysis following the introduction of cenobamate in Italy.
1
—
—